Drugs / INS018_055
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT05975983 | Feb 2024 → Feb 2026 overdue | idiopathic pulmonary fibrosis | InSilico Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT05938920 | Jun 2023 → Aug 2024 | idiopathic pulmonary fibrosis | InSilico Medicine | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07687459 | Aug 2026 → Oct 2029 expected | idiopathic pulmonary fibrosis | InSilico Medicine | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05154240 Comparator | Feb → Dec 2022 | idiopathic pulmonary fibrosis | InSilico Medicine | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INS018_055 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05975983 ↗ |
| Known as | ISM001-055 | “Here we present the results of the first phase 2a multicenter, double-blind, randomized, placebo-controlled trial testing the safety and efficacy of rentosertib (formerly...” PMID 40461817 ↗ Jun 2025 |
| Known as | rentosertib | “Here we present the results of the first phase 2a multicenter, double-blind, randomized, placebo-controlled trial testing the safety and efficacy of rentosertib (formerly...” PMID 40461817 ↗ Jun 2025 |
| Action | Inhibit | “inhibitor of TNIK” PMID 40461817 ↗ Jun 2025 |
| Modality | Small molecule | “a small molecule compound.” NCT05154240 ↗ |
| Route | Oral | “administered as oral doses” NCT05154240 ↗ |
| Target | TNIK | “inhibitor of TNIK” PMID 40461817 ↗ Jun 2025 |